Evidence map›Paper›PMID 32424570›Full record

ReviewCancer chemotherapy and pharmacology2020

Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.

Wenying Angela Liu, Li Yu, Peter N Morcos, Francois Mercier, Barbara J Brennan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenying Angela LiuRoche Innovation Center, New York City, New York, USA.
Li YuRoche Innovation Center, New York City, New York, USA.
Peter N MorcosRoche Innovation Center, New York City, New York, USA.
Francois MercierRoche Innovation Center, Basel, Switzerland.
Barbara J BrennanRoche Innovation Center, New York City, New York, USA. bbrenn@hotmail.com.ORCID http://orcid.org/0000-0001-5980-3017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the translational value of anticancer preclinical models, we retrospectively investigated the relationships between preclinical data and clinical response rate for 42 small-molecule targeted anticancer drugs approved by the US FDA from 2001 to 2018.

methodsFor 42 FDA-approved drugs, relevant pre-clinical (IC

resultsA significant correlation was found between the ratio of free human average plasma concentration (hC

conclusionRelationships were identified for ratios of efficacious clinical exposures to typical preclinical pharmacology data and ORR for KI

Indexed as

Drug ApprovalAnimalsAntineoplastic AgentsDrugs, InvestigationalHumansMiceNeoplasmsProtein Kinase InhibitorsSmall Molecule LibrariesUnited StatesUnited States Food and Drug AdministrationAntineoplastic AgentsDrugs, InvestigationalProtein Kinase InhibitorsSmall Molecule LibrariesEfficacy predictionKinase inhibitorPharmacokineticsRP2D finding

Identifiers

PMID32424570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.